Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Invest Dermatol ; 143(8): 1470-1478.e1, 2023 08.
Artículo en Inglés | MEDLINE | ID: mdl-36804406

RESUMEN

Biologic therapies for psoriasis can cause paradoxical eczema. The role of genetic factors in its pathogenesis is unknown. To identify risk variants, we conducted a GWAS of 3,212 patients with psoriasis, of whom 88 developed paradoxical eczema. Two lead SNPs reached genome-wide significance (P ≤ 5 × 10-8) for association with paradoxical eczema: rs192705221 (near UNC5B, P = 9.52 × 10-10) and rs72925168 (within SLC1A2, P = 1.66 × 10-9). Genome-wide significant SNPs from published GWAS were used to generate polygenic risk scores (PRSs) for atopic eczema, general atopic disease, or a combination, which were tested for association with paradoxical eczema. Improvement over a clinical risk model was assessed by the area under the curve. All three atopy polygenic risk scores were associated with paradoxical eczema (P < 0.05); polygenic risk score for a combination of atopic eczema and general atopic disease had the strongest association (OR = 1.83, 95% CI = 1.17-2.84, P = 0.0078). Including atopic polygenic risk scores in the multivariable model, which included age, sex, atopic background, and psoriatic arthritis history, increased the area under the curve from 0.671 to 0.681-0.686. Atopic genetic burden is associated with paradoxical eczema occurring in biologic-treated patients with psoriasis, indicating shared underlying mechanisms. Incorporating genetic risk may improve treatment outcome prediction models for psoriasis.


Asunto(s)
Productos Biológicos , Dermatitis Atópica , Eccema , Psoriasis , Humanos , Dermatitis Atópica/complicaciones , Eccema/epidemiología , Eccema/genética , Psoriasis/tratamiento farmacológico , Psoriasis/genética , Psoriasis/complicaciones , Factores de Riesgo , Receptores de Netrina
2.
J Pers Med ; 12(8)2022 Jul 30.
Artículo en Inglés | MEDLINE | ID: mdl-36013205

RESUMEN

BACKGROUND: Although telemedicine emerged more than 100 years ago, the recent pandemic underlined the role of remote assessment of different diseases. The diagnoses of cutaneous conditions, especially malignant lesions, have placed significant stress on the fast-track pathway for general practitioners (GPs), dermatologists, and plastic surgeons. The aim of the study was to compare (pre- and during the pandemic) the ability of professionals to face the challenge. METHODS: The study was composed of 1943 consecutive patients (mean age 61.9 ± 18.3, 53.8% female) assessed by GPs, face-to-face (988 patients, 50.8%, between October 2019 and March 2020) and by virtual (video/photo) visits (955 patients, 49.2%, between March 2020 and October 2020) for skin lesions, and referred to secondary care via the two-week wait pathway for suspected skin malignancy. RESULTS: The two groups had similar primary skin malignancies identification rates (24.3% vs. 22.1%, p = 0.25). The virtual visits identified squamous cell carcinoma (SCC) better than face-to-face consultations (p = 0.04), but identified basal cell carcinoma less-well (BCC, p = 0.02), whereas malignant melanoma (MM) was equally identified in the two groups (p = 0.13). There was no difference in the median breach time (days) of the two-week wait pathway (12, IQR = 6 vs. 12, IQR = 5, p = 0.16) in the two groups. Virtual assessments (by GPs) of skin lesions suspected of malignancy, and referred via the two-week wait pathway, increased the probability of diagnosing SCC by 42.9% (p = 0.03), while for malignant melanomas, face-to-face and virtual consultations were alike (p = 0.12). CONCLUSIONS: The equivalent outcomes in the management of skin cancers (SCC, MM) via the two-week pathway through virtual consultations and face-to-face appointments underline the role of telemedicine as a reliable alternative to face-to-face assessments.

4.
Clin Cosmet Investig Dermatol ; 12: 911-917, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31908514

RESUMEN

INTRODUCTION: Vitiligo is one of the most common hypomelanoses. Current treatments include ultraviolet, topical corticosteroids, calcineurin inhibitors. Orally administered vitamins, acting as anti-oxidants and in combination with ultraviolet light have also demonstrated skin re-pigmentation. In our pilot study of seven patients, we injected skin affected with vitiligo intra-dermally with a complex of vitamins and minerals and assessed the outcome. AIM: The aim of this study was to evaluate a novel treatment modality for vitiligo. METHODS: We present a pilot study of seven patients; each having been diagnosed with generalized progressive vitiligo. In all cases, multiple therapies had been previously attempted. All patients were subjected to intradermal injections of biorevitalizant NCTF 135 (3 mls) in the hypo-pigmented areas of skin, once a week for 5 weeks. A 30Gx13 mm needle was used for the 0.025 mls intradermal injections to create micro-papules with a 1 cm distance between the injection sites. The results were assessed at 2 weeks and 5 weeks and were considered successful if partial or complete repigmentation was achieved. RESULTS: Partial or complete skin re-pigmentation post-treatment was observed in vitiligo macules of all patients (100%). No significant side effects, or exacerbation of vitiligo were observed during or after treatment with NCTF 135 in the following 6 months (five patients) and 12 months (two patients). DISCUSSION: Increasing the armamentarium of new treatments of vitiligo is important. Previous studies showed the effectiveness of oral and intramuscularly injected multivitamins in the treatment of vitiligo, explaining the results by the antioxidative qualities of the above. Our study demonstrated that intradermal mesotherapy injections of NCTF135, rich with vitamins and other antioxidants are well tolerated and effective in achieving significant re-pigmentation of de-pigmented skin in all patients studied, including five who had been resistant to previous standard therapies.

5.
Clin Dermatol ; 36(3): 325-337, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29908575

RESUMEN

The use of herbal remedies for various medical issues is becoming increasingly commonplace in all fields of medicine, and dermatology is no exception. This review focuses on traditional dermatologic herbal remedies, commonly used in Russia, as the rich array of 11 different plant zones has resulted in a great variety of medicinal plants. Herbal remedies warrant deeper investigation and research, especially due to their active substance content, which may interfere with or reinforce the effect of modern medications, something that medical professionals should be aware of when prescribing treatments. Although there are a great number of traditional herbal treatments in Russia, only the most commonly used and known treatments and applications will be described as an introduction to the field, which has had many books of varying quality written about it. The preparation and application of treatments for vitiligo, pyodermas, parasitic and infectious skin diseases, acne, dermatitides, rosacea, hyperpigmentation, rhytides, psoriasis, and hyperhidrosis are discussed.


Asunto(s)
Medicina Tradicional , Fitoterapia , Preparaciones de Plantas/uso terapéutico , Envejecimiento de la Piel/efectos de los fármacos , Enfermedades de la Piel/tratamiento farmacológico , Acné Vulgar/tratamiento farmacológico , Dermatitis/tratamiento farmacológico , Humanos , Hiperhidrosis/tratamiento farmacológico , Hiperpigmentación/tratamiento farmacológico , Psoriasis/tratamiento farmacológico , Piodermia/tratamiento farmacológico , Rosácea/tratamiento farmacológico , Federación de Rusia , Enfermedades de la Piel/microbiología , Enfermedades de la Piel/parasitología , Vitíligo/tratamiento farmacológico
6.
Nanoscale Res Lett ; 12(1): 206, 2017 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-28325038

RESUMEN

Erbium-doped fiber amplifiers (EDFAs) for harsh environments require to develop specific fabrication methods of Er 3+-doped fibers (EDFs) so as to limit the impact of radiation-induced absorption. In this context, a compromise has to be found between the concentration of Erbium and the glass composition. On the one hand, high concentration of Er 3+ ions helps to reduce the length of the EDF and hence the cumulated attenuation but generally leads to luminescence quenching mechanisms that limit the performances. On the other hand, so as to avoid such quenching effect, glass modifiers like Al 3+ or P 5+ ions are used in the fabrication of commercial EDFs but are not suitable for applications in harsh environment because these glass modifiers are precursors of radiation-induced structural defects and consequently of optical losses. In this work, we investigate the concept of smart doping via material nanostructuring as a way to fabricate more efficient optical devices. This approach aims at optimizing the glass composition of the fiber core in order to use the minimal content of glass modifiers needed to reach the suited level of performances for EDFA. Er 3+-doped alumina nanoparticles (NPs), as precursor of Er 3+ ions in the preform fabrication process, were used to control the environment of rare-earth ions and their optical properties. Structural and optical characterizations of NP-doped preforms and optical fibers drawn from such preforms demonstrate the interest of this approach for small concentrations of aluminum in comparison to similar glass compositions obtained by a conventional technique.

7.
Contact Dermatitis ; 57(3): 169-72, 2007 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-17680866

RESUMEN

Dicaprylyl maleate (DCM) has been reported rarely as a cause of allergic contact dermatitis. The objectives of this study were to identify patients from multiple centres with allergy to DCM in cosmetic products confirmed by patch testing and, in addition, to investigate the effect of testing with aged DCM. This is an international multicentre study of 22 patients with 26 reactions to products containing DCM. Patch testing was carried out to ingredients including DCM obtained from the manufacturer. Further testing was carried out with deliberately aged DCM in a sample of patients. 22 patients had clinical and positive patch test reactions at 4 days to a total of 26 cosmetic products containing DCM. 5 patients did not react to DCM prepared by the manufacturer from concurrent factory stock but did have positive reactions to a deliberately aged batch of DCM. DCM is an emerging cosmetic allergen. Testing with aged material yields a greater number of positive results. Co-operation between cosmetics manufacturers and clinicians is important in the identification of new allergens.


Asunto(s)
Alérgenos/efectos adversos , Cosméticos/efectos adversos , Dermatitis Alérgica por Contacto/etiología , Emolientes/efectos adversos , Maleatos/efectos adversos , Adulto , Anciano , Cosméticos/química , Dermatitis Alérgica por Contacto/diagnóstico , Femenino , Humanos , Maleatos/química , Persona de Mediana Edad , Pruebas del Parche/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA